Gylongiposide I is a selective inhibitor against the enterovirus EV71 with an EC 50 of 1.53 μM. Gylongiposide I exerts antiviral activity by reducing viral protein VP1 expression and viral genomic RNA levels. Gylongiposide I can be used in the development of anti-EV71 drugs related to hand, foot and mouth disease [1] [2].
References:
[1]. Yin F, et al. Novel dammarane-type glycosides from Gynostemma pentaphyllum. Chem Pharm Bull (Tokyo). 2004 Dec;52(12):1440-4.
[2]. Zhao H, et al. Enzymatic Biotransformation of Gypenoside XLIX into Gylongiposide I and Their Antiviral Roles against Enterovirus 71 In Vitro. Molecules. 2022 Jun 25;27(13):4094.
References:
[1]. Yin F, et al. Novel dammarane-type glycosides from Gynostemma pentaphyllum. Chem Pharm Bull (Tokyo). 2004 Dec;52(12):1440-4.
[2]. Zhao H, et al. Enzymatic Biotransformation of Gypenoside XLIX into Gylongiposide I and Their Antiviral Roles against Enterovirus 71 In Vitro. Molecules. 2022 Jun 25;27(13):4094.